drugset / Trial / NCT05047458
A Study of Single-dose ALXN2050 in Healthy Adults
Phase 1
Completed
28 enrolled
Alexion Pharmaceuticals, Inc.
Achillion, a wholly owned subsidiary of Alexion · collab
RandomizedParallel-groupDouble-blindBasic science
Summary
This was a phase 1, first-in-human, single-center, randomized, double-blind (participants and investigator blind, sponsor open) placebo-controlled, single-ascending dose study of ACH-0145228 (ALXN2050) conducted in healthy adult participants.
Timeline
- Start
- 2017-11-28
- Primary completion
- 2018-04-13
- Completion
- 2018-04-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vemircopan | Small molecule | 40 mg | — |
| Subject | Vemircopan | Small molecule | 80 mg | — |
| Subject | Vemircopan | Small molecule | 120 mg | — |
Indications
No indication recorded.